MedPath
FDA Approval

Regadenoson

FDA-approved pharmaceutical product with comprehensive regulatory information, manufacturing details, and complete labeling documentation.

FDA Approval Summary

Company
Apotex Corp.
DUNS: 845263701
Effective Date
March 14, 2023
Labeling Type
HUMAN PRESCRIPTION DRUG LABEL
Regadenoson(0.08 mg in 1 mL)

Registrants1

Companies and organizations registered with the FDA for this drug approval, including their contact information and regulatory details.

Apotex Inc.

209429182

Products1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

Regadenoson

Product Details

NDC Product Code
60505-6116
Application Number
ANDA207604
Marketing Category
ANDA (C73584)
Route of Administration
INTRAVENOUS
Effective Date
March 14, 2023
Code: 2XLN4Y044HClass: ACTIMQuantity: 0.08 mg in 1 mL
SODIUM PHOSPHATE, DIBASIC, DIHYDRATEInactive
Code: 94255I6E2TClass: IACT
SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATEInactive
Code: 593YOG76RNClass: IACT
EDETATE DISODIUMInactive
Code: 7FLD91C86KClass: IACT
WATERInactive
Code: 059QF0KO0RClass: IACT
PROPYLENE GLYCOLInactive
Code: 6DC9Q167V3Class: IACT
© Copyright 2025. All Rights Reserved by MedPath